MedPath

Mindfulness-based Intervention in COPD Dyads

Not Applicable
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Behavioral: Mindfulness-based stress reduction intervention
Behavioral: Information on stress reduction
Registration Number
NCT04898972
Lead Sponsor
Campus Bio-Medico University
Brief Summary

This study evaluates the effectiveness of a Mindfulness-Based Stress Reduction intervention (MBSRI) on the reduction of stress, anxiety, and depression in people with COPD and their family caregivers. The experimental group will receive the MBSRI and the control group an informational intervention on stress management.

Detailed Description

People affected by Chronic Obstructive Pulmonary Disease (COPD) and their family caregivers (named dyads) often suffer from psychological distress, because of the physical problems and social isolation imposed by the disease. Such psychological distress can influence the ability of patients and caregivers to manage the disease. Mindfulness-based interventions have showed benefits in improving the psychological status in various clinical situations. A 8-week mindfulness based-stress reduction intervention will be offered to a group of COPD patient-caregiver dyads and its effectiveness will be assessed comparing the effects on a control group to whom an informational intervention on stress reduction will be carried out.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Persons able to read and understand Italian.
  • people affected by COPD stage C (GOLD 3 o 4, and/or 2 or more exacerbations per year or 1 or more hospitalizations for exacerbations and score of COPD assessment test-CAT < 10 or mMRC 0-1).
  • People affected by COPD stage D (GOLD 3 o 4, and/or 2 or more exacerbations per year or 1 or more hospitalizations for exacerbations and score of COPD assessment test-CAT ≥ 10 or mMRC ≥ 2).
Exclusion Criteria
  • Persons or dyads not able to guarantee the presence on the MBSR intervention sessions for the four months requested.
  • Persons with diagnosis of anxiety or depression.
  • Persons that have practiced before or actually practice yoga or mindfulness.
  • Persons with cognitive impairment.
  • Persons under continuous oxygen therapy.
  • Persons with diagnosis of cancer or other terminal diseases or any psychiatric problem.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mindfulness-based stress reduction interventionMindfulness-based stress reduction interventionPatient-family caregiver dyads will take part in 8-week Mindfulness-based stress reduction intervention (MBSR).
information bookletInformation on stress reductionPatient-informal caregiver dyads will receive an informative booklet on stress reduction strategies
Primary Outcome Measures
NameTimeMethod
Change from baseline in anxiety level measured by Generalized Anxiety Disorder scale (GAD-7) at 8 weeks and 16 weeks.at baseline, after 8 weeks, and after 16 weeks from baseline

The anxiety level will be measured in patients and caregivers using the 7-item Generalized Anxiety Disorder scale (GAD-7). Its scores range from 0 to 21. Cut points of 5, 10, and 15 represent mild, moderate, and severe levels of anxiety. Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).

Change from baseline in perceived stress measured by Perceived Stress Scale (PSS) at 8 weeks and 16 weeksat baseline, after 8 weeks, and after 16 weeks from baseline

The perceived stress entails the feelings or thoughts that an individual has about how much stress they are under at a given point in time. It will be measured in patients and caregivers using the Perceived Stress Scale (PSS) that is a 10 item-self-report instrument: its score ranges from 0 to to 40 with higher scores indicating higher perceived stress. Scores ranging from 0-13 would be considered low stress. Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).

Change from baseline in depression measured by Patient Health Questionnaire (PHQ-9) at 8 weeks and 16 weeksat baseline, after 8 weeks, and after 16 weeks from baseline

The depressive symptoms in patients and caregivers will be measured using the 9-item Patient Health Questionnaire (PHQ-9). Its score range from 0 (no symptoms) to 27 (nearly daily symptoms). Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively. Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).

Secondary Outcome Measures
NameTimeMethod
Change from baseline in subjective quality of sleep measured by the Pittsburgh Sleep Quality Index (PSQI) at 8 and 16 weeks.at baseline, after 8 weeks, and after 16 weeks from baseline

The quality and patterns of sleep in patients and caregivers will be measured by PSQI that is a self-report questionnaire measuring seven areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. The global score ranges from 0 to 21, the higher the score, the worse the sleep quality. A global score of 5 or more indicates poor sleep quality; Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).

Change from baseline in mindfulness experience measured by Five Facet Mindfulness Questionnaire (FFMQ) at 8 and 16 weeks.at baseline, after 8 weeks, and after 16 weeks from baseline

The mindfulness abilities in patients and caregivers will be measured by a self-reported questionnaire, FFMQ, that comprises 39 items assessing five facets of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience. Higher global score shows a higher mindfulness disposition. Change = (8 weeks- baseline score), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).

Change in impact of the COPD on patient's life measured by COPD Assessment Test (CAT) at 8 weeks and 16 weeksat baseline, after 8 weeks, and after 16 weeks from baseline

The CAT is a 8-item instrument that assesses health-related quality of life and symptom burden in COPD patients. Range of CAT scores from 0-40. Higher scores denote a more severe impact. Change = (8 weeks- baseline scores), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).

Change in health-related quality of life measured by Short Form 12 Health Survey (SF-12) at 8 and 16 weeksat baseline, after 8 weeks, and after 16 weeks from baseline

The physical and mental health-related quality of life of patients and caregivers will by measured by the SF-12 that comprises 12 items. Higher the scores the better the quality of life. Change = (8 weeks- baseline scores), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).

Change in patient's dyspnea measured by the Modified Medical Research Council scale (mMRC) at 8 and 16 weeksat baseline, after 8 weeks, and after 16 weeks from baseline

The mMRC is a 5-point (0-4) scale that will be used to measure the severity of dyspnea in patients. Higher scores mean worse dyspnea. Change = (8 weeks-baseline scores), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).

Trial Locations

Locations (1)

Campus Bio-medico University of Rome

🇮🇹

Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath